We are live on
!
Find out more
SEC
Seven Eight Capital Portfolio holdings
AUM
$1.11B
1-Year Est. Return
29.48%
This Fund
S&P 500
This Quarter
Est. Return
+1.9%
1 Year Est. Return
+29.48%
3 Year Est. Return
+13.61%
5 Year Est. Return
+117.69%
10 Year Est. Return
+239.1%
AUM
$559M
AUM Growth
-$480M
(-46%)
Cap. Flow
-$438M
Cap. Flow
% of AUM
-78.37%
Top 10 Holdings %
Top 10 Hldgs %
15.86%
Holding
756
New
216
Increased
66
Reduced
143
Closed
331
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ALLK
Allakos
ALLK
|
+$25.1M |
| 2 |
Merck
MRK
|
+$9.57M |
| 3 |
INFO
IHS Markit Ltd. Common Shares
INFO
|
+$9.37M |
| 4 |
BridgeBio Pharma
BBIO
|
+$9.02M |
| 5 |
Marvell Technology
MRVL
|
+$7.11M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$10.5M |
| 2 |
Citigroup
C
|
+$10.5M |
| 3 |
Microsoft
MSFT
|
+$9.87M |
| 4 |
OPTU
Optimum Communications Inc
OPTU
|
+$9.41M |
| 5 |
AES
AES
|
+$7.92M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 25.93% |
| 2 | Consumer Discretionary | 17.95% |
| 3 | Healthcare | 12.14% |
| 4 | Communication Services | 8.7% |
| 5 | Financials | 8.43% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
NVTA
276
DELISTED
Invitae Corporation
NVTA
| $497K | 0.09% |
32,516
-4,323
| -12% | -$93.5K |
|
277
TD Synnex
SNX
$21B
| $496K | 0.09% |
+4,341
| New | +$472K |
|
278
Aramark
ARMK
$15B
| $495K | 0.09% |
18,602
+6,446
| +53% | +$169K |
|
279
Lumen
LUMN
$6.27B
| $488K | 0.09% |
+38,908
| New | +$495K |
|
280
Colgate-Palmolive
CL
$74.4B
| $485K | 0.09% |
5,678
-63,445
| -92% | -$4.95M |
|
281
DuPont de Nemours
DD
$19.9B
| $475K | 0.09% |
4,681
-40,796
| -90% | -$3.88M |
|
282
Workday
WDAY
$42.1B
| $470K | 0.08% |
1,722
-13,658
| -89% | -$3.79M |
|
283
Keysight
KEYS
$57.4B
| $469K | 0.08% |
2,272
-25,016
| -92% | -$4.68M |
|
|
B
284
Barrick Mining
B
$68.8B
| $461K | 0.08% |
+24,271
| New | +$461K |
|
|
ACH
285
Accendra Health
ACH
$227M
| $461K | 0.08% |
+10,606
| New | +$416K |
|
286
Dollar General
DG
$28B
| $452K | 0.08% |
1,921
-551
| -22% | -$122K |
|
287
Brown & Brown
BRO
$23.7B
| $449K | 0.08% |
6,388
-13,505
| -68% | -$871K |
|
288
Raymond James Financial
RJF
$34.7B
| $449K | 0.08% |
+4,492
| New | +$444K |
|
289
Generac Holdings
GNRC
$12.8B
| $447K | 0.08% |
+1,271
| New | +$527K |
|
290
Thomson Reuters
TRI
$43B
| $447K | 0.08% |
+3,550
| New | +$442K |
|
291
Recursion Pharmaceuticals
RXRX
$1.68B
| $445K | 0.08% |
+26,001
| New | +$489K |
|
292
LKQ Corp
LKQ
$6.1B
| $440K | 0.08% |
7,323
-24,142
| -77% | -$1.36M |
|
|
SBNY
293
DELISTED
Signature Bank
SBNY
| $439K | 0.08% |
+1,358
| New | +$423K |
|
294
D.R. Horton
DHI
$42.4B
| $433K | 0.08% |
3,996
-19,945
| -83% | -$1.92M |
|
295
W.R. Berkley
WRB
$26.8B
| $433K | 0.08% |
11,833
-3,242
| -22% | -$115K |
|
296
EPAM Systems
EPAM
$5.74B
| $428K | 0.08% |
+641
| New | +$413K |
|
297
Chipotle Mexican Grill
CMG
$43.7B
| $425K | 0.08% |
+12,150
| New | +$428K |
|
298
Fidelity National Financial
FNF
$13.8B
| $425K | 0.08% |
8,480
-48,409
| -85% | -$2.32M |
|
299
Knight Transportation
KNX
$11.5B
| $425K | 0.08% |
6,981
-1,827
| -21% | -$103K |
|
300
Loews
L
$23.7B
| $425K | 0.08% |
+7,363
| New | +$418K |
|
Similar funds
PP
ECM
GCAC
CAM
D
GFS
FTIS
AIA
Seven Eight Capital's Q4 2021 Portfolio in Review
As of Q4 2021, Seven Eight Capital held 756 positions worth $559M, down 46% from $1.04B the previous quarter. Its ten largest holdings account for 16% of the portfolio.
Seven Eight Capital withdrew a net $438M in Q4 2021, closing 331 positions and reducing 143 holdings. Its most notable exit was Bristol-Myers Squibb, an estimated $10.5M position sold in full.
By sector, the portfolio is most concentrated in Technology at 26% of assets, up from 23% a quarter earlier, followed by Consumer Discretionary and Healthcare.
Against the trend, Seven Eight Capital opened a new position in Allakos worth $3M.
- Seven Eight Capital's largest Q4 2021 buy was Allakos: 306,723 shares worth $3M.
- Seven Eight Capital added most to Mimecast Limited in Q4 2021, an estimated $6.07M increase.
- Seven Eight Capital's biggest Q4 2021 reduction was Fidelity National Information Services, cutting an estimated $7.12M.
- Seven Eight Capital fully exited Bristol-Myers Squibb in Q4 2021, selling an estimated $10.5M.
- Seven Eight Capital's ten largest holdings make up 16% of its $559M portfolio in Q4 2021.
- Seven Eight Capital opened 216 new positions and closed 331 in Q4 2021.
- Seven Eight Capital's portfolio value fell 46% quarter-over-quarter to $559M.
Based on Seven Eight Capital's 13F filing for Q4 2021, filed 14 Feb 2022.